Johannes Schecker's research while affiliated with Technische Universität München and other places

Publications (2)

Article
Full-text available
Background: Glioblastoma (GBM) is the most malignant primary brain tumor. Relapse occurs regularly, and the clinical behavior seems to be due to a therapy-resistant subpopulation of glioma-initiating cells that belong to the group of cancer stem cells. Aldehyde dehydrogenase (ALDH) has been identified as a marker for this cell population, and we h...
Article
Aldehyde dehydrogenase is a polymorphic enzyme, which responsible for the oxidation of aldehydes. It has been shown that ALDH1A3 is expressed in human glioblastomas and that its expression correlates with a worse prognosis. In our present study ALDH1A3 expression was associated with resistance against Temozolomide (TMZ) treatment and sensitivity co...

Citations

... In the previous studies, ALDH1A3 has been verified to play a fundamental role in resistance of temozolomide [31]. Nonetheless, there has been none evidence supporting the association of ALDH1A3 and DTX resistance. ...
... The mechanisms through which TMZ induces ROS production (13,27) and some type of autophagic cell deathpossibly ferroptosis -are still unknown (28,29). We hypothesize that they might involve accumulating aldehydes and complex interactions between aldehyde dehydrogenase (ALDH) (26,30), key ferroptosis player GPX4 (13,31), and cystine/cysteine (32). A combination of TMZ and ferroptosis inducing agents thus might be a promising approach in GBM patients (12). ...